This case study shows how MedPharm worked with Reckitt scientists to develop clinically relevant pharynx models for comparing drug delivery from a throat spray and a lozenge formulation. Using ex vivo and human tissue models, the team demonstrated equivalent flurbiprofen permeation across both dosage forms and supported the determination of a clinically relevant dose. These results enabled confident evaluation of formulation performance and helped inform product strategy.
